Literature DB >> 19345298

Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.

Sebastiano Mercadante1, Patrizia Ferrera, Patrizia Villari, Alessandra Casuccio, Giuseppe Intravaia, Salvatore Mangione.   

Abstract

The aim of this study was to prospectively evaluate the frequency, indications, outcomes, and predictive factors associated with opioid switching, using a protocol that had been clinically applied and viewed as effective for many years. A prospective study was carried out on a cohort of consecutive cancer patients who were receiving opioids but had an unacceptable balance between analgesia and adverse effects, despite symptomatic treatment of side effects. The initial conversion ratio between opioids and routes was as follows (mg/day): oral morphine 100=intravenous morphine 33=transdermal fentanyl 1=intravenous fentanyl 1=oral methadone 20=intravenous methadone 16=oral oxycodone 70=transdermal buprenorphine 1.3. The switch was assisted by opioids used as needed, and doses were changed after the initial conversion according to clinical response in an acute care setting. Intensity of pain and symptoms associated with opioid therapy were recorded. A distress score (DS) was calculated as a sum of symptom intensity. A switch was considered successful when the intensity of pain and/or DS, or the principal symptom necessitating the switch, decreased to at least 33% of the value recorded before switching. One hundred eighteen patients underwent opioid substitutions. The indications for opioid switching were uncontrolled pain and adverse effects (50.8%), adverse effects (28.8%), uncontrolled pain (15.2%), and convenience (4.2%). Overall, 103 substitutions were successful. Ninety-six substitutions were successful after the first switching, and a further substitution was successful in seven patients who did not respond to the first switch. The mean time to achieve dose stabilization after switching was 3.2 days. The presence of both poor pain control and adverse effects was related to unsuccessful switching (P<0.004). No relationship was identified between unsuccessful switching and the opioid dose, opioid sequence, pain mechanism, or use of adjuvant medications. Opioid switching was an effective method to improve the balance between analgesia and adverse effects in more than 80% of cancer patients with a poor response to an opioid. The presence of both poor pain relief and adverse effects is a negative factor for switching prognosis, whereas renal failure is not.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19345298     DOI: 10.1016/j.jpainsymman.2007.12.024

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  32 in total

Review 1.  Management of cancer pain.

Authors:  Sebastiano Mercadante
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

Review 2.  Opioid-induced bowel dysfunction.

Authors:  Gyanprakash A Ketwaroo; Vivian Cheng; Anthony Lembo
Journal:  Curr Gastroenterol Rep       Date:  2013-09

3.  Changes of QTc interval after opioid switching to oral methadone.

Authors:  Sebastiano Mercadante; Giovanna Prestia; Claudio Adile; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2013-08-15       Impact factor: 3.603

4.  The poor use of methadone in Italian hospices.

Authors:  Sebastiano Mercadante; Alessandro Valle; Cristina Agnelotti; Amanda Caruselli
Journal:  Support Care Cancer       Date:  2013-03-16       Impact factor: 3.603

Review 5.  Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach.

Authors:  Spencer Dorn; Anthony Lembo; Filippo Cremonini
Journal:  Am J Gastroenterol Suppl       Date:  2014-09-10

6.  Analgesic Requirements in Adolescents Undergoing Bariatric Surgery-an Observational Study.

Authors:  Janelle D Vaughns; Elaine F Williams; Eleanor R Mackey; Jane C Muret; John van den Anker; Evan P Nadler; Zenaide M Quezado
Journal:  Obes Surg       Date:  2019-05       Impact factor: 4.129

Review 7.  The switch from buprenorphine to tapentadol: is it worth?

Authors:  Adriana Miclescu
Journal:  Rom J Anaesth Intensive Care       Date:  2016-10

8.  The opioid rotation ratio of hydrocodone to strong opioids in cancer patients.

Authors:  Akhila Reddy; Sriram Yennurajalingam; Hem Desai; Suresh Reddy; Maxine de la Cruz; Jimin Wu; Diane Liu; Eden Mae Rodriguez; Jessica Waletich; Seong Hoon Shin; Vicki Gayle; Pritul Patel; Shalini Dalal; Marieberta Vidal; Kimberson Tanco; Joseph Arthur; Kimmie Tallie; Janet Williams; Julio Silvestre; Eduardo Bruera
Journal:  Oncologist       Date:  2014-10-23

9.  Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.

Authors:  Raissa Nobrega; Kathy A Sheehy; Caroline Lippold; Amy L Rice; Julia C Finkel; Zenaide M N Quezado
Journal:  Pediatr Res       Date:  2017-09-13       Impact factor: 3.756

10.  Analgesia and central side-effects: two separate dimensions of morphine response.

Authors:  Joanne M Droney; Sophy K Gretton; Hiroe Sato; Joy R Ross; Ruth Branford; Kenneth I Welsh; William Cookson; Julia Riley
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.